1. Japan Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Human Metabolome Technologies, Inc.

Human Metabolome Technologies, Inc.

6090.T
Human Metabolome Technologies, Inc.JP flagTokyo Stock Exchange
610.00
JPY
+1.00
- -
3.39BMarket Cap
Human Metabolome Technologies, Inc.
6090.T
(Tokyo Stock Exchange)

Recent

price

610.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
127.75
145.21
130.23
146.39
160.34
161.34
142.66
- -
190.81
190.64
207.33
220.02
227.58
247.77
227.81
Revenue per Share
-24.52
0.39
-6.59
-13.41
-10.86
-26.92
-61.57
- -
-8.15
9.87
45.39
48.39
41.14
43.67
41.18
Basic EPS, GAAP
-20.88
-1.5
-7.18
-14.4
1.79
-46.01
-61.69
- -
25.46
-10.52
30.15
28.47
34.28
38.28
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
9.93
15.05
- -
Dividend per Share
-90.37
79.92
63.43
50.14
69.96
42.92
-17.77
- -
-62.92
-52.43
-7.01
290.91
322.18
353.18
322.5
Book Value per Share
43.37
366.74
299.33
285.15
325.34
299.87
243.65
- -
206.18
212.92
250.92
296.45
326.27
322.83
326.6
Tangible Book Value per Share
4
4
5
5
6
6
6
- -
6
6
6
6
6
6
6
Basic Weighted Avg Shares
496
610
687
780
914
938
834
- -
1,118
1,124
1,223
1,299
1,346
1,455
1,346
Sales/Revenue/Turnover
-21.12
-2.02
-14.64
-9.02
-4.74
-15.02
-43.79
- -
-1.52
3.5
15.63
16.24
16.36
17.15
16.36
Operating Margin (%)
49
37
71
61
53
61
64
- -
48
56
65
80
86
104
- -
Depreciation Expense
-95
2
-35
-71
-62
-157
-360
- -
-48
58
268
286
243
256
243
Net Income, GAAP
- -
72.69
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
7.12
4.94
7.12
Effective Tax Rate (%)
-19.19
0.27
-5.06
-9.16
-6.77
-16.68
-43.16
- -
-4.27
5.18
21.89
21.99
18.08
17.62
18.08
Profit Margin (%)
172
1,511
1,497
1,342
1,689
1,641
1,232
1,098
1,111
1,140
1,196
1,355
1,463
1,415
1,463
Working Capital
86
55
31
6
- -
32
22
20
10
33
23
13
11
3
11
LT Debt
174
1,548
1,583
1,523
1,859
1,753
1,437
1,214
1,215
1,260
1,487
1,772
1,947
1,909
1,947
Total Equity
- -
-0.33
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
9.73
11.23
9.73
Return on Invested Capital (%)
- -
1.63
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
12.03
11.99
12.03
Return on Capital (%)
- -
- -
-10.36
-23.76
-18.59
-48.28
- -
- -
- -
- -
- -
- -
13.43
12.89
13.43
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'24
Jun'24
ST Debt
211
211
215
LT Borrowings
- -
- -
- -
LT Finance Leases
8
18
11
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6
6
6
Market Capitalization
3,780
3,869
3,733

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'24
Jun'24
Total Current Assets
1,792
2,081
2,096
Cash, Cash Equivalents & STI
1,424
1,654
1,789
Accounts Receivable, Net
308
384
228
Inventories
36
30
37
Total Current Liabilities
411
535
633
Payables & Accruals
- -
- -
- -
ST Debt
211
211
215
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.17%
9.75%
-1.96%
Free Cash Flow
- -
-100.48%
10.9%
Net Income, GAAP
- -
27.09%
5.42%
Sales/Revenue/Turnover
- -
5.45%
8.12%
Total Cash Common Dividend
- -
- -
50.58%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
235
398
483
230
1,346
2025
- -
- -
- -
- -
1,455
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-6.47
- -
- -
- -
41.14
2025
- -
- -
- -
- -
43.67
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
9.93
2025
- -
- -
- -
- -
15.05
2026
- -
- -
- -
- -
- -
Similar Companies
SeqLL Inc. (SQLLW)
Shanghai Labway Clinical Laboratory Co., Ltd. (301060.SZ)
Mettler-Toledo International Inc. (MTD)
Genomic Vision S.A. (GV.PA)
Health S.A. (MLAHC.PA)
Instituto Hermes Pardini S.A. (PARD3.SA)
Business
Human Metabolome Technologies, Inc. (Ticker: 6090.T) is a biotechnology company specializing in metabolomics research and analysis services. The company provides comprehensive metabolome analysis, including mass spectrometry-based metabolic profiling; targeted and non-targeted metabolomics; biomarker discovery; clinical trial support; and reagent development for metabolomics research. Its core offerings encompass human, animal, and microbial metabolome analysis services aimed at pharmaceutical, academic, and industrial clients worldwide. Human Metabolome Technologies operates primarily in Japan and internationally, supporting drug development, diagnostics, and life science research since its founding in 2003 and is headquartered in Tsuruoka, Yamagata, Japan. In the last 1-2 years, the company has expanded its service portfolio with enhanced metabolite databases and reagent product launches aimed at improving research accuracy and throughput, alongside forming strategic collaborations with global pharmaceutical and academic institutions to bolster metabolomics applications. These partnerships focus on advancing precision medicine through metabolic biomarker discovery and application in therapeutic development. Human Metabolome Technologies continues to adapt to market demands by leveraging advanced analytical technologies and expanding its global footprint in metabolomics solutions. The company operates within the biotechnology and life sciences industries, targeting pharmaceutical companies, research institutions, and healthcare sectors. It maintains subsidiaries and collaborative networks to enhance its research capabilities and service delivery. Human Metabolome Technologies integrates cutting-edge technology with biological data analysis to offer robust metabolomics solutions facilitating innovation in medical and biological research.